Thr387
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr387  -  MST1 (human)

Site Information
tMKRRDEtMQPAKPs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450050
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 , 4 ) , mass spectrometry ( 3 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 ) , mutation of modification site ( 10 ) , phospho-antibody ( 1 , 2 , 4 , 10 ) , western blotting ( 1 , 2 , 4 , 10 )
Disease tissue studied:
breast cancer ( 4 ) , leukemia ( 1 ) , T cell leukemia ( 1 ) , liver cancer ( 2 ) , hepatocellular carcinoma ( 2 ) , pancreatic cancer ( 4 ) , pancreatic carcinoma ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
COL4A1 (human) ( 2 )
Putative in vivo kinases:
Akt1 (human) ( 10 )
Kinases, in vitro:
Akt1 (human) ( 10 )
Putative upstream phosphatases:
PHLPP (human) ( 4 )
Phosphatases, in vitro:
PHLPP (human) ( 4 )
Treatments:
EGF ( 10 ) , GF109203X ( 10 ) , LY294002 ( 10 ) , PD98059 ( 10 ) , pictilisib ( 1 ) , SCH772984 ( 1 ) , siRNA ( 10 ) , wortmannin ( 10 )

Downstream Regulation
Effects of modification on MST1:
enzymatic activity, induced ( 4 ) , enzymatic activity, inhibited ( 10 ) , intracellular localization ( 10 ) , phosphorylation ( 10 ) , protein stabilization ( 10 )
Effects of modification on biological processes:
apoptosis, altered ( 4 ) , apoptosis, inhibited ( 10 )

References 

1

Nováková J, Talacko P, Novák P, Vališ K (2019) The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells. Cells 8
30795621   Curated Info

2

Wong KF, et al. (2016) Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget 7, 77683-77695
27765911   Curated Info

3

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

4

Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23
20513427   Curated Info

5

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

6

Moritz A (2009) CST Curation Set: 7296; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

7

Moritz A (2009) CST Curation Set: 7297; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

8

Zhou J (2009) CST Curation Set: 6054; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

9

Possemato A (2008) CST Curation Set: 5543; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

10

Jang SW, Yang SJ, Srinivasan S, Ye K (2007) Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J Biol Chem 282, 30836-44
17726016   Curated Info

11

Moritz A (2007) CST Curation Set: 2969; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

12

Possemato A (2007) CST Curation Set: 2733; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

13

Moritz A (2007) CST Curation Set: 2479; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info